【レポートの概要（一部）】
1. Report Overview
1.1 Breast Cancer Drugs Overview
1.2 Why you Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Breast Cancer and its Treatment
2.1 What is Breast Cancer?
2.2 The Second Most Common Cancer in the World
2.3 Normal Structure of the Human Breast
2.4 Classifying the Different Types of Breast Cancer
2.4.1 Pathology
2.4.2 Molecular Subtype
2.4.3 Stages
2.4.4 Grades
2.5 Treatment Protocols
2.5.1 Treatment Options for Localised Disease
2.5.1.1 The Different Types of Therapy for Localised Breast Cancer
2.5.1.2 Stage 0 – Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS)
2.5.1.3 Adjuvant Chemotherapy and Adjuvant Hormonal Therapy Treatment Options for Stage 1-3 Localised Disease
2.5.2 Treatment Options for Recurrent or Metastatic Disease
3. Leading Breast Cancer Drugs
3.1 Herceptin (trastuzumab) by Roche: The Leading Breast Cancer Drug
3.1.1 Approved Indications: Breast Cancer is the Main Indication
3.1.2 Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
3.1.3 Total Herceptin Revenues 2010-2015
3.1.4 The Threat of Biosimilars
3.1.4.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
3.1.4.2 Herzuma (Celltrion)
3.1.4.3 Total Biosimilar Trastuzumab Revenue Forecast, for all Indications, 2016-2026
3.1.5 Herceptin for Breast Cancer Revenue Forecast 2016-2026
3.2 Perjeta (pertuzumab) by Roche
3.2.1 Is a Recent Addition to the Market, Approved for Different Stages of Breast Cancer
3.2.2 Positive Results from Different Clinical Trials
3.2.3 Total Perjeta Revenues 2012-2015
3.2.4 Perjeta for Breast Cancer Revenue Forecast 2016-2026
3.3 Afinitor (everolimus) by Novartis
3.3.1 Multiple Approved Indications but Breast Cancer Leads
3.3.2 No Extension to HER2 Positive Breast Cancer, as Afinitor Fails to Meet Primary Objective in Phase 3 Trial
3.3.3 NICE Rejects Afinitor on Cost Basis, although Drug Remains on the Cancer Drugs Fund, Despite Rumours it Would be Removed
3.3.4 Total Afinitor Revenues 2010-2015
3.3.5 Afinitor for Breast Cancer Revenue Forecast 2016-2026
3.4 Faslodex (fulvestrant) by AstraZeneca
3.4.1 Approved for Breast Cancer all the Way Back in 2002, Higher Dose Approved in 2010
3.4.2 Patent Dispute with Mylan
3.4.3 Total Faslodex Revenues 2010-2015
3.4.4 Faslodex for Breast Cancer Revenue Forecast 2016-2026
3.5 Ibrance (palbociclib) by Pfizer
3.5.1 Accelerated Approval on the Back of Promising Data
3.5.2 Has Already Been Used to Treat Over 15,000 Patients, MAA Filed in Europe
3.5.3 Total Ibrance Revenues Q1-Q4 2015
3.5.4 Ibrance for Breast Cancer Revenue Forecast 2016-2026
3.6 Avastin (bevacizumab) by Roche
3.6.1 Multiple Approved Indications, Still Approved for Breast Cancer in Major Markets, Except for the US
3.6.1.1 Why was the FDA-Breast Cancer Label Withdrawn?
3.6.2 Total Avastin Revenues 2010-2015
3.6.3 Avastin for Breast Cancer Revenue Forecast 2016-2026
3.6.4 No Biosimilars Approved yet, but Multiple Candidates in Clinical Trials
3.6.5 Total Biosimilar Bevacizumab Revenue Forecast, for all Indications, 2016-2026
3.7 Kadcyla (ado-trastuzumab emtansine) by Roche
3.7.1 The First Antibody-Drug Conjugate to be Approved for Breast Cancer
3.7.2 Mixed Results from Different Clinical Trials
3.7.3 Total Kadcyla Revenues 2013-2015
3.7.4 Kadcyla for Breast Cancer Revenue Forecast 2016-2026
3.8 Femara (letrozole) by Novartis
3.8.1 Hormone Therapy for Early Breast Cancer
3.8.2 Total Femara Revenues 2010-2025
3.8.3 Femara for Breast Cancer Revenue Forecast 2016-2026
3.9 Abraxane (paclitaxel Protein-Bound) by Celgene
3.9.1 Breast Cancer was the first of its Approved Indications
3.9.2 Total Abraxane Revenues 2010-2015
3.9.3 Abraxane for Breast Cancer Revenue Forecast 2016-2026
4. Breast Cancer Drugs R&D Pipeline 2016-2026
4.1 Roche: Not Content with Dominating Current Market, Already Grooming Future Leaders
4.1.1 Taselisib (GDC-0032 / RG7604)
4.1.1.1 Positive Results from Phase 1 Trial
4.1.2 Atezolizumab (MPDL3280A / RG7446)
4.1.2.1 Early Results in Triple-Negative Breast Cancer
4.1.3 Investigating Kadcyla and Perjeta in Wider Breast Cancer Indications
4.2 Novartis
4.2.1 Buparlisib (BKM120)
4.2.1.1 Early-Results for Buparlisib in Combination with Olaparib
4.2.2 Alpelisib (BYL719)
4.2.3 Ribociclib (LEE011)
4.2.3.1 Phase 1b Results in Combination with Femara
4.3 AstraZeneca
4.3.1 AZD5363
4.3.1.1 Well Tolerated and Yielding Partial Response in Early Results from 2013
4.3.2 MEDI-573 (In Partnership with MedImmune)
4.4 Abemaciclib (LY2835219) by Eli Lilly
4.4.1 Coveted Breakthrough Therapy Designation from the FDA
4.5 Veliparib (ABT-888) by AbbVie
4.6 Ganetespib by Synta Pharmaceuticals
4.7 Entinostat by Syndax Pharmaceuticals
4.7.1 Syndax Collaborating with Merck and Roche, Breakthrough Therapy Designation
4.8 Lucitanib by Clovis Oncology
4.9 Glembatumumab vedotin (CDX-011) by Celldex Therapeutics
4.9.1 Results from EMERGE Study
4.10 MM-302 by Merrimack
4.10.1 Phase 1 Results Released April 2015
4.11 Neratinib (PB272) by Puma Biotechnology
4.12 ENMD-2076 by CASI Pharmaceuticals
4.13 Margetuximab by MacroGenics
5. Global Breast Cancer Drugs Market 2016-2026
5.1 The Global Breast Cancer Drugs Market Forecast 2016-2026
5.2 What Factors will Drive Growth in the Global Breast Cancer Drugs Market?
5.3 Increasing Rate of Breast Cancer
5.3.1 What Factors are Contributing to this Increase?
5.4 Dynamic and Lucrative Sector with Strong R&D Pipeline
5.5 The Use of Combination Therapies Brings Various Benefits to Both Patients and Companies
5.6 What Factors will Restrain Growth in the Breast Cancer Drugs Market?
5.7 Patent Expiries for Key Drugs Will Open up Market to Generic and Biosimilar Competition
5.8 Declining Healthcare Budgets Lead to Cost Pressures
5.9 New Therapies that Only Offer Modest Benefits over Existing Treatments, and Intense Competition
5.10 SWOT Analysis of the Global Breast Cancer Drugs Market
6. Leading Therapeutic Segments and National Markets within the Global Breast Cancer Drugs Market
6.1 The Main Therapeutic Segments within the Breast Cancer Drugs Market, Forecast 2016-2026
6.1.1 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.1.2 Monoclonal Antibodies (mAbs) Segment Forecast 2016-2026
6.1.3 Chemotherapy and Hormone Therapy Segment
6.1.4 Kinase Inhibitor Segment Forecast 2016-2026
6.1.5 ‘Other’ Segment Forecast 2016-2026
6.2 Leading National Markets for Breast Cancer Drugs
6.2.1 Leading Regional Markets for Breast Cancer, Forecast 2016-2026
6.2.2 Regional Composition of the Market in 2015, 2020 and 2026
6.2.3 US Breast Cancer Drugs Market 2016-2026
6.2.3.1 The Dominant National Market, and will Remain so Throughout the Forecast Period, Although is Undergoing Some Changes
6.2.3.2 US Breast Cancer Drugs Market Forecast 2016-2026
6.2.4 EU5 Breast Cancer Drugs Market 2016-2026
6.2.4.1 German Breast Cancer Drugs Market: The Leading EU Market, Undergoing Reforms
6.2.4.2 German Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.3 French Breast Cancer Drugs Market: Some Reduction in Healthcare Spending, but National Healthcare System Remains Strong
6.2.4.4 French Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.5 Italian Breast Cancer Drugs Market: Facing Challenges
6.2.4.6 Italian Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.7 UK Breast Cancer Drugs Market: Pricing is a Contentious Issue
6.2.4.8 UK Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.9 Spanish Breast Cancer Drugs Market
6.2.4.10 Spanish Breast Cancer Drugs Market Forecast 2016-2026
6.2.5 Japanese Breast Cancer Drugs Market
6.2.5.1 Rapidly Ageing Population will Boost the Market, but will a Successful Generic Market be Established?
6.2.5.2 Japanese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6 BRIC Breast Cancer Drugs Market
6.2.6.1 Chinese Breast Cancer Drugs Market: Nation to Become one of the Major Global Players due to Rapid Growth
6.2.6.2 Chinese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.3 Brazilian Breast Cancer Drugs Market: Healthcare in the Country is Taking Great Strides Forward
6.2.6.4 Brazilian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.5 Russian Breast Cancer Drugs Market: Punches Below its Weight
6.2.6.6 Russian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.7 Indian Breast Cancer Drugs Market: Generics are King
6.2.6.8 Indian Breast Cancer Drugs Market Forecast 2016-2026
7. Research Interviews
7.1 Interview with Dr Ken Ren, CEO of CASI Pharmaceuticals
7.1.1 On ENMD-2076 for Triple Negative Breast Cancer
7.1.2 Status of the Chinese Oncology Market
7.1.3 On the Properties that will Allow CASI to compete Against Giants in the Market, Such as Roche
7.1.4 On Drivers and Restraints for the Market
7.1.5 On the Challenges of Developing a Pipeline Product for the Breast Cancer Market, and Ways of Overcoming Them
7.2 Interview with MacroGenics
7.2.1 On Margetuximab for Metastatic Breast Cancer
7.2.2 On Where Margetuximab would fit into the Competitive HER2 Space
7.2.3 On the Challenges of Developing a Pipeline Product
8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How will the Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：乳がん治療薬の世界市場：モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他■ 英文：Breast Cancer Drugs Market 2016-2026 : Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals
■ 発行日：2016年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041534
■ 調査対象地域：グローバル
- 使い捨て気道診断装置の世界市場2019-2023About this market Lung disorders such as lunh cancer, tuberculosis, and pneumonia can affect the airways and lungs. They are primarily caused by dust, microbial infection, air pollution, smoke from tobacco products, and occupational chemicals. Lung disorders impact the air sacs (alveoli), which can lead to pulmonary edema. In such cases, single-use airway diagnostic devices are used to examine the …
- 医用画像解析ソフトウェアの世界市場：タイプ別（スタンドアロン）、画像タイプ別（2D、3D、4D）、モダリティ別（CT、MRI、PET、超音波）、用途別（整形外科、歯科、腫瘍、腎臓疾患）、エンドユーザー別（病院、診断センター、研究）、地域別予測Global Medical image software analysis Market to reach USD 4.9 billion by 2025. Global Medical image software analysis Market valued approximately USD 2.41 billion in 2016 is anticipated to grow with a healthy growth rate of more than 8.1% over the forecast period 2017-2025. Key success factors for this market are; technological advancements in medical imaging systems & analysis software, growing …
- Japanese Hospital Tumor Marker Testing Market 2014This new report from Venture Planning Group contains 537 pages, 42 tables, and presents a comprehensive analysis of the Japanese hospital tumor marker testing market, including: Major issues pertaining to the Japanese hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. M …
- 医薬品有力企業シリーズ：主要医薬品製造受託機関(CMO)分析[Contract manufacturing for pharma – discover top companies’ revenue prospects] How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s new report shows you their prospects to 2024. There you discover that industry and market’s results, trends, opportunities and prospects, also with predicted revenues and profits. Our study analyses 30 top CMOs. There you see how revenu …
- グルテンフリー製品の世界市場分析：製品別（製パン、乳製品代替品、デザート･アイスクリーム、調理済み食品、パスタ･ライス）、流通別（食料品店、量販店、クラブストア）、セグメント予測、2014-2025The global gluten-free products market is expected to reach USD 33.05 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness substantial growth over the forecast period mainly on account of the rising incidences of celiac disease, diabetes as well as obesity across the developed economies.Consumer perception of gluten-free products being diet food …
- クラウド実現技術の世界市場：仮想化、オートメーション、サービス指向アーキテクチャ（SOA）About Cloud-enabling Technologies Cloud computing came into existence through advancement in the field of hardware, software, and networking. The evolution of cloud computing is made possible through technologies such as virtualization, automated computing, and service-oriented architecture (SOA). These technologies are commonly termed as cloud-enabling technologies. Cloud computing provides an op …
- 石油化学キャパシティー増加と最新開発動向（2014年2月）Petrochemical Capacity Additions and Recent Developments - February 2014 Summary The petrochemical industry witnessed various construction activities throughout the globe with most of the news coming from Asia-Pacific. There were six major project related announcements with one announcement each in Saudi Arabia, Germany, Iran, Thailand, India and the US. In India, JBF Petrochemicals moved ahead wi …
- 米国のスパ市場2016-2020About the Spa Market in the US Owing to today’s hectic lifestyles, the need for de-stressing is gaining utmost importance. This factor, coupled with the growing demand for exclusive beauty services and treatments, is driving the spa market in the US. To address the growing demand for spa services across the country and to increase their profit margins, vendors are focusing more on expanding their …
- モジュール工法の世界市場：タイプ別（常設、再配置可能）、材料別（プレキャストコンクリート、鋼鉄、木材、プラスチック）、モジュール別、最終用途分野別、地域別予測Global Modular Construction Market to reach USD 149.4 billion by 2025. Global Modular Construction Market valued approximately USD 85 billion in 2017 is anticipated to grow with a healthy growth rate of more than 7.30% over the forecast period 2017-2025. Modular construction is prefabricated buildings that are manufactured in a plant. It offers significant advantages compared to conventional build …
- デジタル印刷の世界市場予測（～2023年）：プリンタ、インキ、プリントヘッドAccording to MarketsandMarkets’ forecast, the digital printing market, in terms of value, is expected to grow from USD 22.18 Billion in 2017 to USD 28.85 Billion by 2023, at a CAGR of 4.48% between 2017 and 2023. Major drivers for the market are the growing demand for sustainable printing, development of packaging and textile industries, and reduction in per unit cost of printing with digital prin …
- PHM(集団健康管理)の世界市場：製品別（ソフトウェア、サービス）、最終用途別（納税者、プロバイダ―、雇用者グループ）、地域別、セグメント予測The global population health management market size is expected to reach USD 101.0 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 20.7% during the forecast period. The need for population health services that combine multiple functionalities is increasing, due to the complex nature of care delivery and payment models. PHM solutions can …
- 熱画像ソリューションの世界市場：熱画像装置、ソフトウェア、サービスThermal Imaging is changing the world with the applications ranging from military to personal handheld cameras and smartphones. The global thermal imaging market has witnessed a significant demand owing to the increasing adoption of related devices across a diverse range of applications. The thermal imaging market is fast gaining traction primarily due to decreasing cost and increasing usage in va …
- 動物遺伝学の世界市場予測（～2023年）“Global animal genetics market is projected to grow at a CAGR of 6.5%”The global animal genetics market is projected to reach USD 5.8 billion by 2023 from USD 4.2 billion in 2018, at a CAGR of 6.5 % during the forecast period. Factors such as rising consumption for animal-derived protein, growing population and rapid urbanization across the globe, increased adoption of genetic services and advance …
- 世界の太陽電池用ペースト市場2015The Global Solar Cell Paste Industry Report 2015 is a professional and in-depth study on the current state of the Solar Cell Paste industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Solar Cell Paste market analysis is provided for the international markets including development trends, competitive lan …
- 軍用インフラ及び物流サービスの世界市場2016-2020About Military Infrastructure and Logistics Resources The role of military infrastructure and logistics resources involves planning, processing, and controlling the physical flows of essential goods and supplies from the point of origin to the military bases in a cost efficient approach. The concept of a structured logistics system was introduced in military service during World War II. Over the y …
